Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
Boston Scientific (NYSE: BSX) has completed its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK) for $27.50 per share, representing an enterprise value of approximately $1.18 billion. This acquisition strengthens Boston Scientific's vascular technology solutions by integrating the innovative transcarotid artery revascularization (TCAR) platform for stroke prevention and carotid artery disease treatment.
The deal is expected to have a minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, becoming accretive thereafter. The impact on GAAP earnings may be less favorable due to amortization expenses and acquisition-related charges. This strategic move aims to expand the availability of TCAR to more physicians and patients through Boston Scientific's extensive commercial network.
Boston Scientific (NYSE: BSX) ha completato l'acquisizione di Silk Road Medical, Inc. (Nasdaq: SILK) per 27,50 dollari per azione, che rappresenta un valore d'impresa di circa 1,18 miliardi di dollari. Questa acquisizione rafforza le soluzioni tecnologiche vascolari di Boston Scientific integrando la piattaforma innovativa di revascolarizzazione transcarotidea (TCAR) per la prevenzione degli ictus e il trattamento delle malattie arteriose carotidi.
Si prevede che l'operazione avrà un impatto minimo sugli utili per azione rettificati di Boston Scientific nel 2024 e 2025, diventando accrescitiva successivamente. L'impatto sugli utili GAAP potrebbe essere meno favorevole a causa delle spese di ammortamento e delle spese relative all'acquisizione. Questa mossa strategica mira ad ampliare la disponibilità del TCAR a più medici e pazienti grazie alla vasta rete commerciale di Boston Scientific.
Boston Scientific (NYSE: BSX) ha completado su adquisición de Silk Road Medical, Inc. (Nasdaq: SILK) por 27,50 dólares por acción, lo que representa un valor empresarial de aproximadamente 1,18 mil millones de dólares. Esta adquisición fortalece las soluciones tecnológicas vasculares de Boston Scientific al integrar la innovadora plataforma de revascularización transcarotídea (TCAR) para la prevención de accidentes cerebrovasculares y el tratamiento de enfermedades de la arteria carótida.
Se espera que el acuerdo tenga un impacto mínimo en las ganancias ajustadas por acción de Boston Scientific en 2024 y 2025, siendo acumulativo posteriormente. El impacto en las ganancias GAAP puede ser menos favorable debido a los gastos de amortización y cargos relacionados con la adquisición. Este movimiento estratégico tiene como objetivo ampliar la disponibilidad de TCAR a más médicos y pacientes a través de la extensa red comercial de Boston Scientific.
보스턴 사이언티픽(Boston Scientific) (NYSE: BSX)은 실크 로드 메디컬(Silk Road Medical, Inc.) (Nasdaq: SILK)을 주당 27.50달러에 인수 완료했습니다. 이는 약 11억 8천만 달러의 기업 가치를 나타냅니다. 이번 인수는 뇌졸중 예방 및 경동맥 질환 치료를 위한 혁신적인 경동맥 재관류 플랫폼(Transcarotid Artery Revascularization, TCAR)을 통합하여 보스턴 사이언티픽의 혈관 기술 솔루션을 강화합니다.
이번 거래는 2024년과 2025년 보스턴 사이언티픽의 조정 주당 수익에 미치는 영향이 최소화될 것으로 예상되며, 이후부터 수익이 증가할 것으로 보입니다. GAAP 수익에 미치는 영향은 상각 비용과 인수 관련 비용 때문에 덜 우호적일 수 있습니다. 이 전략적 수단은 보스턴 사이언티픽의 광범위한 상업 네트워크를 통해 더 많은 의사와 환자에게 TCAR의 접근성을 확장하는 것을 목표로 하고 있습니다.
Boston Scientific (NYSE: BSX) a finalisé son acquisition de Silk Road Medical, Inc. (Nasdaq: SILK) pour 27,50 dollars par action, représentant une valeur d'entreprise d'environ 1,18 milliard de dollars. Cette acquisition renforce les solutions technologiques vasculaires de Boston Scientific en intégrant la plateforme innovante de revascularisation transcarotidienne (TCAR) pour la prévention des AVC et le traitement des maladies de l'artère carotide.
On s'attend à ce que l'opération ait un impact minimal sur les bénéfices ajustés par action de Boston Scientific en 2024 et 2025, devenant accretive par la suite. L'impact sur les bénéfices GAAP pourrait être moins favorable en raison des frais d'amortissement et des coûts liés à l'acquisition. Ce mouvement stratégique vise à étendre la disponibilité du TCAR à davantage de médecins et de patients grâce à l'importante réseau commercial de Boston Scientific.
Boston Scientific (NYSE: BSX) hat die Übernahme von Silk Road Medical, Inc. (Nasdaq: SILK) für 27,50 US-Dollar pro Aktie abgeschlossen, was einem Unternehmenswert von etwa 1,18 Milliarden US-Dollar entspricht. Diese Übernahme stärkt die vaskulären Technologielösungen von Boston Scientific, indem die innovative transkarotidale Arterienrevascularisierung (TCAR) Plattform zur Schlaganfallprävention und Behandlung von Erkrankungen der Karotisarterie integriert wird.
Es wird erwartet, dass der Deal minimale Auswirkungen auf die bereinigten Erträge pro Aktie von Boston Scientific in 2024 und 2025 haben wird, und danach akquisitiven Einfluss hat. Die Auswirkungen auf die GAAP-Erträge könnten aufgrund von Amortisationskosten und akquisitionsbezogenen Gebühren weniger günstig sein. Dieser strategische Schritt zielt darauf ab, die Verfügbarkeit von TCAR für mehr Ärzte und Patienten über das umfangreiche Handelsnetzwerk von Boston Scientific zu erweitern.
- Acquisition of Silk Road Medical strengthens Boston Scientific's vascular technology portfolio
- Integration of TCAR platform expands treatment options for carotid artery disease
- Potential for improved patient outcomes and reduced stroke risk
- Expected to be accretive to adjusted earnings per share after 2025
- Leverages Boston Scientific's commercial reach to expand TCAR availability
- Significant acquisition cost of $1.18 billion
- Immaterial impact on adjusted earnings per share in 2024 and 2025
- Potential dilution to GAAP earnings due to amortization and acquisition-related charges
Insights
The acquisition of Silk Road Medical by Boston Scientific for
- Expected to be earnings neutral in the short term (2024-2025)
- Potentially accretive to adjusted EPS beyond 2025
- GAAP earnings may be less favorable due to amortization and acquisition-related charges
This acquisition aligns with industry trends of larger medtech companies acquiring innovative smaller firms to boost their product offerings and market share. The neutral short-term financial impact suggests a focus on long-term growth and market positioning rather than immediate earnings boost.
The acquisition of Silk Road Medical brings the innovative TCAR (transcarotid artery revascularization) platform into Boston Scientific's portfolio, representing a significant advancement in stroke prevention and carotid artery disease treatment. Key medical implications:
- TCAR offers a minimally invasive alternative to traditional carotid endarterectomy
- Potential for reduced stroke risk during and after the procedure
- Wider access to TCAR through Boston Scientific's extensive distribution network
This move could accelerate the adoption of TCAR, potentially improving patient outcomes in carotid artery disease treatment. The integration of this technology into a major medtech company's portfolio may also spur further research and development in this field, potentially leading to refinements and improvements in the TCAR technique.
Boston Scientific's acquisition of Silk Road Medical is a strategic play in the growing market for minimally invasive vascular treatments. Market implications:
- Strengthens Boston Scientific's position in the vascular intervention segment
- Potential for increased market share in the carotid artery disease treatment space
- Aligns with the trend towards less invasive surgical procedures
This acquisition could reshape the competitive landscape in the vascular device market, potentially pressuring other players to innovate or consolidate. The
"Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients through our significant commercial reach," said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific. "The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes."
The acquisition includes a purchase price of
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding financial and business impact of the transaction and anticipated benefits of the transaction, business plans and strategy, product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include, among other things: economic, political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the transaction and successfully integrate Silk Road Medical's operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the transaction; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.
CONTACTS:
Blake Rouhani
Media Relations
(763) 494-2268
blake.rouhani@bsci.com
Jon Monson
Investor Relations
(508) 683-5450
BSXInvestorRelations@bsci.com
i Enterprise value of approximately
View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-closes-acquisition-of-silk-road-medical-inc-302250314.html
SOURCE Boston Scientific Corporation
FAQ
What is the acquisition price for Silk Road Medical by Boston Scientific (BSX)?
How will the Silk Road Medical acquisition affect Boston Scientific's (BSX) earnings?
What technology does Boston Scientific (BSX) gain from acquiring Silk Road Medical?
When did Boston Scientific (BSX) complete the acquisition of Silk Road Medical?
